Stocks · News reference

BridgeBio Pharma To Present Two Oral Presentations, Three Posters On New Acoramidis Data In Individuals With Transthyretin Amyloid Cardiomyopathy At European Society Of Cardiology Congress 2026

Aug 24, 2026, 11:32 AMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 26, 2026, 11:31 AMBenzinga Newsdesk
BridgeBio Pharma Doses First Patient In ASCEND-ATTR Trial To Evaluate Effects Of Acoramidis To Enhance Cardiac Structure, Function, And Amyloid Burden In Individuals With Transthyretin Amyloid Cardiomyopathy
BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today
Read original at benzinga
BBIO
SEC EDGARAug 17, 2026, 1:05 PMSEC EDGAR
8-K filing — BridgeBio Pharma, Inc. (BBIO)
Filed: 2026-08-17 AccNo: 0001140361-26-033282 Size: 477 KB Item 1.01: Entry into a Material Definitive Agreement Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read original at edgar
BBIO
The Motley FoolAug 14, 2026, 3:15 PMEric Volkman
BridgeBio Stock Has Soared 29% in Just 3 Months. Here's Why Wall Street Thinks It Could Go Even Higher.
BridgeBio Pharma's stock has surged 29% in three months, driven by strong performance of its FDA-approved heart medication Attruby, which saw sales more than triple year-over-year to $222 million in Q2. With 16 out of 17 analysts recommending a buy and three promising drugs in late-stage development under FDA review, Wall Street believes the stock has further upside potential despite the company remaining unprofitable.
Read original at the-motley-fool
BBIO